Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy

Non-clinical studies of systemic delivery of oncolytic virus arms with IL-12 and anti-PD-1 antibody

New generation of oncolytic herpesviruses embodying immunotherapeutic genes encoding IL-12 and anti-PD-1 antibody

A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of T3011 in Advanced Cutaneous or Subcutaneous Malignancies

New generation of oncolytic herpesviruses embodying immunotherapeutic genes encoding IL-12 and anti-PD-1 antibody

Enhancement of Oncolytic Activity of oHSV Expressing IL-12 and Anti-PD-1 Antibody by Concurrent Administration of Exosomes Carrying CTLA-4 MiRNA

MiR-H28 and miR-H29 expressed late in productive infection are exported and restrict HSV-1 replication and spread in recipient cells

Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity

MiRNAs Targeting ICP4 and Delivered to Susceptible Cells in Exosomes Block HSV-1 Replication in a Dose-Dependent Manner